Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC.ATOS · Entity 7556 | Director | May 12, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATOSSA THERAPEUTICS, INC.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,683 |
Reported balance
After 2026-05-12 transaction · row 1
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 10,000 · Balance 10,683 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 14, 2026 20:26 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-224140 · ownership.xml · nonDerivative · entry 1 Remmel H. Lawrence · CIK 0001551817 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,683 F1 · shares: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:05 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000950170-25-073516 · ownership.xml · derivative · entry 1 Remmel H. Lawrence · CIK 0001551817 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-05-15 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over 12 months following May 15, 2025, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued on May 15, 2025 with an exercise price of $0.99, representing the closing stock price on May 15, 2025. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:00 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | PurchaseCommon Stock | 10,000 | $0.70 | $7,000.00 |
DisclosureSEC source: 0000950170-25-046742 · ownership.xml · nonDerivative · entry 1 Remmel H. Lawrence · CIK 0001551817 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,257 F1 · balance_after: Reflects a reverse stock split of the Issuer's common stock at a ratio of 12:1 effective April 2018. The Reporting Person disclaims beneficial ownership of 11 shares of common stock owned by his spouse except to the extent of his pecuniary interest in the shares. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 20:00 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0000950170-24-079562 · ownership.xml · derivative · entry 1 Remmel H. Lawrence · CIK 0001551817 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-06-27 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over 12 months following June 27, 2024, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued at approximately 9:30 a.m. (ET) on June 27, 2024 with an exercise price of $1.05, representing the most recently reported closing stock price on June 26, 2024. Read SEC document |
| May 04, 2023 Filed May 5, 2023 23:36 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001437749-23-012871 · rdgdoc.xml · derivative · entry 1 Remmel H. Lawrence · CIK 0001551817 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-04 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. The options were issued at approximately 9:50 a.m. (ET) on May 4, 2023, with an exercise price of $0.662, representing the most recently reported closing stock price on May 3, 2023. Read SEC document |
| May 13, 2022 Filed May 16, 2022 22:21 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001437749-22-012711 · rdgdoc.xml · derivative · entry 1 Remmel H. Lawrence · CIK 0001551817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-05-13 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 9:30 a.m. (ET) on May 13, 2022, with an exercise price of $0.93, representing the most recently reported closing stock price on May 12, 2022. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:18 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001437749-21-012673 · rdgdoc.xml · derivative · entry 1 Remmel H. Lawrence · CIK 0001551817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 4:30 p.m. (ET) on May 14, 2021 with an exercise price of $2.90, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| May 15, 2020 Filed May 19, 2020 18:06 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001437749-20-011265 · rdgdoc.xml · derivative · entry 1 Remmel H. Lawrence · CIK 0001551817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 4:30 p.m. (ET) on May 15, 2020 with an exercise price of $1.70, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| May 17, 2019 Filed May 22, 2019 00:07 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001437749-19-010645 · rdgdoc.xml · derivative · entry 1 Remmel H. Lawrence · CIK 0001551817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-05-17 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 9:00 a.m. (ET) on May 17, 2019 with an exercise price of $2.52, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:04 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001615774-18-006000 · s111133_form4.xml · derivative · entry 1 Remmel H. Lawrence · CIK 0001551817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Read SEC document |
| May 24, 2017 Filed May 26, 2017 17:50 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 57,685 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001615774-17-002745 · s106364_form4.xml · derivative · entry 1 Remmel H. Lawrence · CIK 0001551817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,369 Underlying: Common Stock · 57,685 shares Expires 2027-05-24 F1 · shares: Pursuant to the policies of Pryor Cashman, the law firm of which Mr. Remmel is a partner, the options Mr. Remmel receives for his services as a director are assigned to the firm. F2 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. F1 · derivative.underlying_shares: Pursuant to the policies of Pryor Cashman, the law firm of which Mr. Remmel is a partner, the options Mr. Remmel receives for his services as a director are assigned to the firm. F1 · balance_after: Pursuant to the policies of Pryor Cashman, the law firm of which Mr. Remmel is a partner, the options Mr. Remmel receives for his services as a director are assigned to the firm. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 21:10 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | PurchaseCommon Stock | 2,500 | $0.63 | $1,580.00 |
DisclosureSEC source: 0001615774-17-001757 · s105907_form4.xml · nonDerivative · entry 1 Remmel H. Lawrence · CIK 0001551817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,126 F1 · balance_after: The Reporting Person disclaims beneficial ownership of the 133 shares of common stock held by the Reporting Person's spouse and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of the 133 shares of common stock held by the Reporting Person's spouse and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.